CCMEP™ is the only credential that designates qualified individuals as Certified CME Professionals.
Test Development in
Buy Tarceva (Erlotinib) tablets online on NCCME
How and where to order Erlotinib HCl (Tarceva) 150 mg tablets online:
|Shop:||MEDS FOR SALE
|Prices:||from $34.30 per pill
|Discount:||5% coupon: 5OFF
|Forms:||Tarceva (Erlotinib Hydrochloride) 150 mg tablets
|Type:||Erlotinib brand, Erlonat brand, Tarceva generic
|Payment:||Visa, Mastercard, AmEx, Bitcoin
|Delivery:||Standard airmail and trackable courier service
|Shipping:||Worldwide, including USA, UK, Europe, Canada, Australia
Indications and usage:
Maintenance treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) whose disease has not progressed after four cycles of platinum-based first-line chemotherapy.
Treatment of locally advanced or metastatic non-small cell lung cancer after failure of at least one prior chemotherapy regimen.
First-line treatment of patients with locally advanced, unresectable or metastatic pancreatic cancer, in combination with gemcitabine.
Dosage and administration:
The dose for NSCLC is 150 mg/day.
The dose for pancreatic cancer is 100 mg/day.
All doses of Tarceva should be taken on an empty stomach at least one hour before or two hours after food.
Reduce in 50 mg decrements, when necessary.
Dosage forms and strengths:
Tarceva (Erlotinib Hydrochloride) film-coated tablets for oral use: 25 mg, 100 mg, and 150 mg.
Withhold erlotinib in patients with an overdose or suspected overdose and institute symptomatic treatment.
Warnings and precautions:
Interstitial lung disease (ILD): Occurs in 1.1% of patients. Withhold Tarceva for acute onset of new or progressive unexplained pulmonary symptoms, such as dyspnea, cough and fever. Discontinue Erlotinib if ILD is diagnosed.
Renal failure: Monitor renal function and electrolytes, particularly in patients at risk of dehydration. Withhold Tarceva for severe renaltoxicity.
Hepatotoxicity: Occurs with or without hepatic impairment, including hepatic failure and hepatorenal syndrome: Monitor periodic liver testing. Withhold or discontinue Tarceva (Erlotinib Hydrochloride) for severe or worsening liver tests.
Gastrointestinal perforations: Discontinue this drug.
Bullous and exfoliative skin disorders: Discontinue Tarceva.
Cerebrovascular accident (CVA): The risk of CVA is increased in patients with pancreatic cancer.
Microangiopathic hemolytic anemia (MAHA): The risk of MAHA is increased in patients with pancreatic cancer.
Ocular disorders: Discontinue this medication for corneal perforation, ulceration or persistent severe keratitis.
Hemorrhage in patients taking warfarin: Regularly monitor INR in patients taking warfarin or other coumarin-derivative anticoagulants.
Embryo-fetal toxicity: Can cause fetal harm. Advise females of reproductive potential of the potential risk to the fetus and to use effective contraception.
CYP3A4 inhibitors or a combined CYP3A4 and CYP1A2 inhibitor increase erlotinib plasma concentrations. Avoid concomitant use. If not possible, reduce Tarceva dose.
CYP3A4 inducers decrease erlotinib plasma concentrations. Avoid concomitant use. If not possible, increase Erlotinib dose.
Cigarette smoking and CYP1A2 inducers decrease erlotinib plasma concentrations. Avoid concomitant use. If not possible, increase Tarceva dose.
Drugs that increase gastric pH decrease erlotinib plasma concentrations. For proton pump inhibitors avoid concomitant use if possible. For H-2 receptor antagonists, take this medicine 10 hours after H-2 receptor antagonist dosing. For use with antacids, separate dosing by several hours.
Use in specific populations:
Lactation: Do not breastfeed.
Adverse reactions, side effects:
The most common adverse reactions (>20%) in maintenance treatment are rash-like events and diarrhea.
The most common adverse reactions (>20%) in 2nd line NSCLC are rash, diarrhea, anorexia, fatigue, dyspnea, cough, nausea, infection and vomiting.
The most common adverse reactions (>20%) in pancreatic cancer are fatigue, rash, nausea, anorexia, diarrhea, abdominal pain, vomiting, weight decrease, infection, edema, pyrexia, constipation, bone pain, dyspnea, stomatitis and myalgia.
Where to buy erlotinib online:
To purchase Erlotinib HCl (Tarceva) 150 mg tablets from reliable online pharmacies and drugstores please use resources described above on this webpage.